<SEC-DOCUMENT>0001410368-14-000793.txt : 20141128
<SEC-HEADER>0001410368-14-000793.hdr.sgml : 20141127
<ACCEPTANCE-DATETIME>20141126174622
ACCESSION NUMBER:		0001410368-14-000793
CONFORMED SUBMISSION TYPE:	NSAR-B
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140930
FILED AS OF DATE:		20141128
DATE AS OF CHANGE:		20141126
EFFECTIVENESS DATE:		20141128

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEKLA LIFE SCIENCES INVESTORS
		CENTRAL INDEX KEY:			0000884121
		IRS NUMBER:				043147016
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		NSAR-B
		SEC ACT:		1940 Act
		SEC FILE NUMBER:	811-06565
		FILM NUMBER:		141254601

	BUSINESS ADDRESS:	
		STREET 1:		2 LIBERTY SQUARE
		STREET 2:		9TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
		BUSINESS PHONE:		6177728515

	MAIL ADDRESS:	
		STREET 1:		2 LIBERTY SQUARE
		STREET 2:		9TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	H&Q LIFE SCIENCES INVESTORS
		DATE OF NAME CHANGE:	19920929
</SEC-HEADER>
<DOCUMENT>
<TYPE>NSAR-B
<SEQUENCE>1
<FILENAME>answer.fil
<DESCRIPTION>NSAR B
<TEXT>
<PAGE>      PAGE  1
000 B000000 09/30/2014
000 C000000 0000884121
000 D000000 N
000 E000000 NF
000 F000000 Y
000 G000000 N
000 H000000 N
000 I000000 6.1
000 J000000 A
001 A000000 TEKLA LIFE SCIENCES INVESTORS
001 B000000 811-6565
001 C000000 6177728500
002 A000000 2 LIBERTY SQUARE 9TH FLOOR
002 B000000 BOSTON
002 C000000 MA
002 D010000 02109
003  000000 N
004  000000 N
005  000000 N
006  000000 N
007 A000000 N
007 B000000  0
007 C010100  1
008 A000001 TEKLA CAPITAL MANAGEMENT LLC
008 B000001 A
008 C000001 801-000000
008 D010001 BOSTON
008 D020001 MA
008 D030001 02109
010 A000001 STATE STREET BANK AND TRUST CO.
010 B000001 85-85003
010 C010001 BOSTON
010 C020001 MA
010 C030001 02111
012 A000001 COMPUTERSHARE TRUST CO. N.A.
012 B000001 85-113400
012 C010001 CANTON
012 C020001 MA
012 C030001 02021
013 A000001 DELOITTE & TOUCHE LLP
013 B010001 BOSTON
013 B020001 MA
013 B030001 02110
015 A000001 STATE STREET BANK & TRUST CO.
015 B000001 C
015 C010001 BOSTON
015 C020001 MA
015 C030001 02110
015 E010001 X
018  000000 Y
019 A000000 Y
<PAGE>      PAGE  2
019 B000000    3
019 C000000 TEKLAFUNDS
020 A000001 J P MORGAN SECURITIES INC
020 B000001 13-3224013
020 C000001     60
020 A000002 NATIONAL FINANCIAL SERVICES CORP.
020 B000002 04-2785576
020 C000002     37
020 A000003 BANK OF NEW YORK MELLON
020 B000003 13-5160382
020 C000003     37
020 A000004 JEFFERIES & CO.
020 B000004 95-2622900
020 C000004     19
020 A000005 GOLDMAN SACHS & CO.
020 B000005 13-5108880
020 C000005     18
020 A000006 WEDBUSH MORGAN SECURITIES, INC.
020 B000006 95-2495390
020 C000006     17
020 A000007 BANK OF AMERICA CORP.
020 B000007 95-4035346
020 C000007     17
020 A000008 MIZUHO CORPORATE BANK LTD.
020 B000008 13-5624234
020 C000008     12
020 A000009 PIPER JAFFRAY & CO.
020 B000009 41-0953246
020 C000009      8
020 A000010 Wells Fargo Securities, LLC
020 B000010 94-3379992
020 C000010      8
021  000000      250
022 A000001 STATE STREET BANK AND TRUST CO.
022 B000001 04-1867445
022 C000001   2065299
022 D000001     77418
022 A000002 CITIBANK, N.A.
022 B000002 13-5266470
022 C000002     25600
022 D000002         0
022 A000003 JEFFERIES & CO.
022 B000003 95-2622900
022 C000003      3481
022 D000003         0
022 A000004 NOMURA SECURITIES CO. LTD.
022 B000004 13-2642206
022 C000004      1350
022 D000004         0
022 A000005 NEUROVANCE, INC
022 C000005       763
<PAGE>      PAGE  3
022 D000005         0
022 A000006 Insightra Medical, Inc.
022 C000006       620
022 D000006         0
022 A000007 J P MORGAN SECURITIES INC
022 B000007 13-3224013
022 C000007       335
022 D000007        92
022 A000008 CARDIOKINETIX, INC.
022 C000008       241
022 D000008         0
022 A000009 ILLUMINOSS MEDICAL, INC
022 C000009       228
022 D000009         0
022 A000010 Celladon Corporation
022 C000010        25
022 D000010         0
023 C000000    2097942
023 D000000      77510
024  000000 N
026 A000000 N
026 B000000 Y
026 C000000 N
026 D000000 Y
026 E000000 N
026 F000000 N
026 G010000 N
026 G020000 N
026 H000000 N
027  000000 N
028 A010000         0
028 A020000         0
028 A030000         0
028 A040000         0
028 B010000         0
028 B020000         0
028 B030000         0
028 B040000         0
028 C010000         0
028 C020000         0
028 C030000         0
028 C040000         0
028 D010000         0
028 D020000         0
028 D030000         0
028 D040000         0
028 E010000         0
028 E020000         0
028 E030000         0
028 E040000         0
028 F010000         0
<PAGE>      PAGE  4
028 F020000         0
028 F030000         0
028 F040000         0
028 G010000         0
028 G020000         0
028 G030000         0
028 G040000         0
028 H000000         0
030 A000000      0
030 B000000  0.00
030 C000000  0.00
031 A000000      0
031 B000000      0
032  000000      0
033  000000      0
035  000000      0
036 B000000      0
038  000000      0
042 A000000   0
042 B000000   0
042 C000000   0
042 D000000   0
042 E000000   0
042 F000000   0
042 G000000   0
042 H000000   0
043  000000      0
044  000000      0
045  000000 Y
046  000000 N
047  000000 N
048  000000  0.000
048 A010000        0
048 A020000 0.000
048 B010000        0
048 B020000 0.000
048 C010000        0
048 C020000 0.000
048 D010000        0
048 D020000 0.000
048 E010000        0
048 E020000 0.000
048 F010000        0
048 F020000 0.000
048 G010000        0
048 G020000 0.000
048 H010000        0
048 H020000 0.000
048 I010000        0
048 I020000 0.000
048 J010000        0
<PAGE>      PAGE  5
048 J020000 0.000
048 K010000        0
048 K020000 0.000
049  000000 N
050  000000 N
051  000000 N
052  000000 N
053 A000000 Y
053 B000000 Y
053 C000000 N
054 A000000 Y
054 B000000 N
054 C000000 Y
054 D000000 N
054 E000000 N
054 F000000 N
054 G000000 N
054 H000000 N
054 I000000 N
054 J000000 Y
054 K000000 N
054 L000000 N
054 M000000 Y
054 N000000 N
054 O000000 N
055 A000000 N
055 B000000 N
056  000000 N
057  000000 N
058 A000000 N
059  000000 Y
060 A000000 Y
060 B000000 Y
061  000000        0
062 A000000 N
062 B000000   0.0
062 C000000   0.0
062 D000000   0.0
062 E000000   0.0
062 F000000   0.0
062 G000000   0.0
062 H000000   0.0
062 I000000   0.0
062 J000000   0.0
062 K000000   0.0
062 L000000   0.0
062 M000000   0.0
062 N000000   0.0
062 O000000   0.0
062 P000000   0.0
062 Q000000   0.0
<PAGE>      PAGE  6
062 R000000   0.0
063 A000000   0
063 B000000  0.0
066 A000000 Y
066 B000000 N
066 C000000 Y
066 D000000 N
066 E000000 N
066 F000000 N
066 G000000 N
067  000000 N
068 A000000 N
068 B000000 N
069  000000 N
070 A010000 Y
070 A020000 Y
070 B010000 Y
070 B020000 Y
070 C010000 N
070 C020000 N
070 D010000 Y
070 D020000 N
070 E010000 N
070 E020000 N
070 F010000 Y
070 F020000 N
070 G010000 Y
070 G020000 N
070 H010000 Y
070 H020000 N
070 I010000 N
070 I020000 N
070 J010000 Y
070 J020000 Y
070 K010000 Y
070 K020000 Y
070 L010000 Y
070 L020000 Y
070 M010000 Y
070 M020000 N
070 N010000 Y
070 N020000 N
070 O010000 Y
070 O020000 N
070 P010000 N
070 P020000 N
070 Q010000 N
070 Q020000 N
070 R010000 Y
070 R020000 N
071 A000000    153378
<PAGE>      PAGE  7
071 B000000    105992
071 C000000    346181
071 D000000   31
072 A000000 12
072 B000000      233
072 C000000      644
072 D000000        0
072 E000000        0
072 F000000     3818
072 G000000       76
072 H000000        0
072 I000000       57
072 J000000       98
072 K000000       46
072 L000000       36
072 M000000      167
072 N000000        0
072 O000000        0
072 P000000        0
072 Q000000        0
072 R000000      113
072 S000000      167
072 T000000        0
072 U000000        0
072 V000000        0
072 W000000      134
072 X000000     4712
072 Y000000       69
072 Z000000    -3766
072AA000000    29304
072BB000000        0
072CC010000    63729
072CC020000        0
072DD010000        0
072DD020000        0
072EE000000    27403
073 A010000   0.0000
073 A020000   0.0000
073 B000000   1.7000
073 C000000   0.0000
074 A000000        2
074 B000000     4132
074 C000000        0
074 D000000     8999
074 E000000    26580
074 F000000   398569
074 G000000        0
074 H000000        0
074 I000000     5939
074 J000000        0
074 K000000        0
<PAGE>      PAGE  8
074 L000000      126
074 M000000      495
074 N000000   444842
074 O000000      141
074 P000000      347
074 Q000000        0
074 R010000        0
074 R020000        0
074 R030000        0
074 R040000      267
074 S000000        0
074 T000000   444087
074 U010000    19006
074 U020000        0
074 V010000    23.37
074 V020000     0.00
074 W000000   0.0000
074 X000000      215
074 Y000000        0
075 A000000        0
075 B000000   355708
076  000000    22.10
077 A000000 Y
077 B000000 Y
077 C000000 Y
077 Q010000 N
077 Q020000 N
077 Q030000 N
078  000000 N
080 A000000 ICI MUTUAL INSURANCE COMPANY
080 C000000     3000
081 A000000 Y
081 B000000   3
082 A000000 Y
082 B000000       25
083 A000000 N
083 B000000        0
084 A000000 N
084 B000000        0
085 A000000 Y
085 B000000 N
086 A010000   4011
086 A020000  79934
086 B010000      0
086 B020000      0
086 C010000      0
086 C020000      0
086 D010000      0
086 D020000      0
086 E010000      0
086 E020000      0
<PAGE>      PAGE  9
086 F010000      0
086 F020000      0
087 A010000 Tekla LIFE SCIENCES INVESTORS
087 A020000 87911K100
087 A030000 HQL
088 A000000 N
088 B000000 N
088 C000000 N
088 D000000 N
SIGNATURE   LAURA WOODWARD
TITLE       TREASURER

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.77B ACCT LTTR
<SEQUENCE>2
<FILENAME>hqlnsaretter77b.txt
<DESCRIPTION>EXHIBIT 77B
<TEXT>
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Trustees of Tekla Life Sciences Investors

In planning and performing our audit of the financial statements of Tekla
Life Sciences Investors (formerly H&Q Life Sciences Investors) (the Fund)
as of and for the year ended September 30, 2014, in accordance with the
standards of the Public Company Accounting Oversight Board (United States),
we considered the Fund's internal control over financial reporting, including
controls over safeguarding securities, as a basis for designing our
auditing procedures for the purpose of expressing our opinion on the financial
statements and to comply with the requirements of Form N-SAR, but not for the
purpose of expressing an opinion on the effectiveness of the Funds
internal control over financial reporting. Accordingly, we express no
such opinion.

The management of the Fund is responsible for establishing and maintaining
effective internal control over financial reporting. In fulfilling this
responsibility, estimates and judgments by management are required to assess
the expected benefits and related costs of controls. A companys internal
control over financial reporting is a process designed to provide reasonable
assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally
accepted accounting principles. A company's internal control over financial
reporting includes those policies and procedures that (1) pertain to the
maintenance of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the company;
(2) provide reasonable assurance that transactions are recorded as necessary
to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures of the
company are being made only in accordance with authorizations of management
and directors of the company; and (3) provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use, or
disposition of a company's assets that could have a material effect on the
financial statements.

Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that
controls may become inadequate because of changes in conditions or that the
degree of compliance with the policies or procedures may deteriorate.

A deficiency in internal control over financial reporting exists when the
design or operation of a control does not allow management or employees,
in the normal course of performing their assigned functions, to prevent or
detect misstatements on a timely basis. A material weakness is a deficiency,
or a combination of deficiencies, in internal control over financial reporting,
such that there is a reasonable possibility that a material misstatement of
the companys annual or interim financial statements will not be prevented
or detected on a timely basis.

Our consideration of the Funds internal control over financial reporting was
for the limited purpose described in the first paragraph and would not
necessarily disclose all deficiencies in internal control that might be
material weaknesses under standards established by the Public Company
Accounting Oversight Board (United States). However, we noted no deficiencies
in the Funds internal control over financial reporting and its operation,
including controls for safeguarding securities, that we consider to be a
material weakness, as defined above, as of September 30, 2014.

This report is intended solely for the information and use of management and
the Board of Directors of Tekla Life Sciences Investors and the Securities
andExchange Commission and is not intended to be and should not be used by
anyone other than these specified parties.

DELOITTE & TOUCHE LLP
Boston, Massachusetts
November 21, 2014





</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.77C VOTES
<SEQUENCE>3
<FILENAME>hqlvotingresults77c.txt
<DESCRIPTION>EXHIBIT 77C
<TEXT>
An Annual Meeting of Shareholders was held on June 9, 2014. Shareholders voted
to elect Trustees of the Fund to hold office for a term of three years or until
their respective successors shall have been duly elected and qualified. The
following votes were cast with respect to each of the nominees:

                             For               Withheld
Michael W. Bonney         13,058,116            258,449
Oleg M. Pohotsky          13,042,971            273,594
William S. Reardon, CPA   13,069,821            246,744

Michael W. Bonney, William S. Reardon, CPA and Oleg M. Pohotsky were elected
to serve until the 2017 Annual Meeting.

Trustees serving until the 2015 Annual Meeting are Rakesh K. Jain, Ph.D.,
Daniel R. Omstead, Ph.D. and Lucinda H. Stebbins, CPA.

Trustee serving until the 2016 Annual Meeting is Uwe E. Reinhardt.

Shareholders ratified the appointment of Deloitte & Touche LLP as the
independent registered public accountants of the Fund for the fiscal year
ending September 30, 2014 by the following

   For          Against        Abstain
13,110,024      99,245         107,295
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
